Data sheet

IFTA AG
Certified QMS according to
DIN EN ISO 9001
Reg. No. IC 03214 034

Jena Bioscience

VZV-gE (residues 48-135)
Varicella-zoster Virus Glycoprotein E
recombinant, *E. coli*

Cat. No.	Amount
PR-1253	100 µg

For *in vitro* use only
Quality guaranteed for 12 months
Store at -20°C

Avoid freeze / thaw cycles

Form
Liquid. Supplied in 25 mM Tris-HCl pH 8.0, 1 mM EDTA and 50% glycerol.

Application
Antigen in ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.

Specificity
Immunoreactive with sera of VZV-infected individuals.

Purity
>95% by SDS-PAGE

Description
The protein contains the VZV-gE immunodominant regions, amino acids 48-135.
The protein is purified by proprietary chromatographic technique.

Background
Varicella-zoster virus (VZV) is an extremely cell-associated alpha herpesvirus. It interacts with cell surface heparan sulfate proteoglycans during virus attachment.
VZV-gE is a glycoprotein that plays an active or supportive role in VZV cell membrane fusion. VZV-gE was found to enhance the fusogenic potential of VZV gB.

Selected References:

Maresova *et al.* (2005) Incorporation of three endocytosed varicellazoster virus glycoproteins, gE, gH, and gB, into the virion envelope. *J. Virol.* **79**:997.
Taha *et al.* (2004) Are false negative direct immunfluorescence assays caused by varicella zoster virus gE mutant strains? *J. Med. Virol.* **73**:631.
Pasieka *et al.* (2004) Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. *J. Virol.* **78**:2884.
Mo *et al.* (2002) The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. *Virology.* **304**:176.
Kenyon *et al.* (2002) Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. *J. Virol.* **76**:10980.
Jaquet *et al.* (2002) Immunogenicity of a recombinant varicellazoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. *Vaccine.* **20**:1593.